Novel Agonist Bioisosteres and Common Structure-Activity Relationships for The Orphan G Protein-Coupled Receptor GPR139 by Shehata, Mohamed A et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Novel Agonist Bioisosteres and Common Structure-Activity Relationships for The
Orphan G Protein-Coupled Receptor GPR139
Shehata, Mohamed A; Jensen, Anne Cathrine Nøhr; Lissa, Delphine; Bisig, Christoph; Isberg,
Vignir; Andersen, Kirsten B; Harpsøe, Kasper; Björkling, Fredrik; Bräuner-Osborne, Hans;
Gloriam, David E
Published in:
Scientific Reports
DOI:
10.1038/srep36681
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Shehata, M. A., Jensen, A. C. N., Lissa, D., Bisig, C., Isberg, V., Andersen, K. B., ... Gloriam, D. E. (2016). Novel
Agonist Bioisosteres and Common Structure-Activity Relationships for The Orphan G Protein-Coupled Receptor
GPR139. Scientific Reports, 6, 1-13. [36681]. https://doi.org/10.1038/srep36681
Download date: 03. Feb. 2020
1Scientific RepoRts | 6:36681 | DOI: 10.1038/srep36681
www.nature.com/scientificreports
Novel Agonist Bioisosteres and 
Common Structure-Activity 
Relationships for The Orphan G 
Protein-Coupled Receptor GPR139
Mohamed A. Shehata1,*, Anne C. Nøhr1,*, Delphine Lissa1,†, Christoph Bisig1,‡, Vignir Isberg1,§, 
Kirsten B. Andersen1,2,$, Kasper Harpsøe1, Fredrik Björkling1, Hans Bräuner-Osborne1,# & 
David E. Gloriam1,#
GPR139 is an orphan class A G protein-coupled receptor found mainly in the central nervous system. 
It has its highest expression levels in the hypothalamus and striatum, regions regulating metabolism 
and locomotion, respectively, and has therefore been suggested as a potential target for obesity and 
Parkinson’s disease. The two aromatic amino acids L-Trp and L-Phe have been proposed as putative 
endogenous agonists, and three structurally related benzohydrazide, glycine benzamide, and 
benzotriazine surrogate agonist series have been published. Herein, we assayed 158 new analogues 
selected from a pharmacophore model, and identified 12 new GPR139 agonists, containing previously 
untested bioisosteres. Furthermore, we present the first combined structure-activity relationships, and 
a refined pharmacophore model to serve as a rationale for future ligand identification and optimization.
G protein-coupled receptors (GPCRs) constitute the largest family of human membrane proteins1. GPCRs 
induce cellular signalling upon activation by a range of endogenous ligand types, including neurotransmitters, 
hormones, nutrients, peptides, and ions2. Approximately 1/3 of all marketed drugs act on GPCRs3. While many 
GPCRs are well-characterized there are still more than 120 non-olfactory orphan receptors with unknown endog-
enous ligand(s) and/or function4.
GPR139 is an orphan receptor identified from bioinformatics analysis of the human genome5. It has been 
shown to have a high mRNA expression in the brain, particularly in the striatum and hypothalamus6–8 – suggest-
ing that GPR139 could be involved in movement control7–9 and/or the regulation of food intake/metabolism6,10. 
GPR139 is thus a potential target for the treatment of Parkinson’s disease, obesity, eating disorders, and/or diabe-
tes. The main signal transduction pathway of GPR139 is still not established, as signalling through Gq6,10–12, Gs9, 
Gi8 and G12/137 have all been demonstrated. This ambiguity could be caused by a number of underlying reasons, 
including lack of studies of cells endogenously expressing the receptor, uncertainty about the endogenous ligand, 
the use of different cell lines as expression systems, and/or assay variations.
We have previously shown, that aromatic dipeptides and the endogenous L-amino acids tryptophan (L-Trp) 
and phenylalanine (L-Phe) (Fig. 1) can activate GPR13910 (EC50 of 220, and 320 μ M, respectively). In addition, 
Liu et al. recently reported6,13 that L-Trp and L-Phe stimulate [35S]GTPγ S binding in membranes from COS7 cells 
(EC50 of 26 μM and 31 μM, respectively), a concentration-dependent calcium response in HEK293 cells (EC50 
of 49 μM, and 60 μM, respectively), and calcium mobilization in HEK293 (EC50 of 287 μM and 411 μM, respec-
tively). This shows that these two aromatic amino acids activate GPR139, with EC50 values in the 30–300 μM 
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range. However, it cannot be excluded that the physiological activation of GPR139 is mediated by another more 
potent endogenous ligand.
Surrogate small molecule ligands for GPR139 have been reported by Hu et al.9, Shi et al. from Lundbeck A/
S11, Dvorak et al. from Jansen R&D13,14, and Hitchcock et al. from Takeda Pharmaceutical Company Limited15. 
The most potent surrogate agonists are compounds 1a (EC50 = 39 nM), 7c (EC50 = 16 nM), and 39 (EC50 = 6 nM), 
from Shi et al., Dvorak et al. and Hitchcock et al., respectively (Fig. 1 and Tables 1, 2 and 3). Herein, we have 
screened our pharmacophore model10 against ~6 million drug-like compounds to identify more diverse agonist 
analogues, and conducted a joint structure-activity relationship (SAR) study together with the three published 
series.
Results
New agonist ligands and bioisosteres. Our search for GPR139 ligands featured an initial pharmacoph-
ore screening followed by three cycles of assaying in the Fluo-4 Ca2+-assay and analogue purchases, and covered 
in total 158 compounds (Supplementary Chart 1). This yielded 12 novel GPR139 agonists with efficacies similar 
to compound 1a (EC50 = 39 nM) and potencies ranging from 364 nM to 4.7 μM (Fig. 2 and Table 4). These contain 
previously untested bioisosteres of the terminal aromatic systems (Table 5), as well as variations of the linker com-
pared to the published reference agonists. The 12 novel agonists did not show activity in the CHO-M1 receptor 
cell line in the Fluo-4 Ca2+-assay, indicating specific interactions with the GPR139.
Characterisation of the preferred signalling pathway. Due to the different signalling pathway 
reported in the literature6,10–12, we tested two of the most potent known surrogate agonists; 7c and 1a, the 
L-Trp and L-Phe and the submicromolar compounds (DL43, DL126, DL24, DL22, DL132 and DL130) in the 
cAMP dynamic 2 assay (CisBio) and IP-One HTRF® assay (CisBio) to check for biased signalling in the Gs, Gi 
and Gq coupled assay. None of the tested compounds induced Gs response in CHO-139 or in CHO-M1 cells 
(Supplementary Fig. 1), which was included as a control. Furthermore none of the tested compounds were able 
to inhibit the cAMP response induced by 5 μ M forskolin in the CHO-139 cells by activating Gi, except L-Trp, 
which inhibits the 5 μ M forskolin induced cAMP response by more than 10% in high concentrations, indicating 
Gi activation (Supplementary Fig. 2). However, this response was seen in both CHO-139 and CHO-M1 and is 
therefore an unspecific response. Hence, based on our data the compounds described herein activate GPR139 
in CHO-k1 cells through the Gq pathway, which is shown with both the Fluo-4 Ca2+-assay (Fig. 2 and Table 4) 
and the IP-One assay (Fig. 3A and Table 6). Furthermore, we show that the compounds activate CHO-GPR139 
specifically through GPR139, as no response is seen in CHO-M1 cells (Fig. 3B).
Overall there was a good correlation between potencies observed in the Fluo-4 Ca2+-assay and the IP-One 
assay with compounds generally being 10–40 fold more potent in the former. This has been observed previously 
and has been ascribed to spare receptors where only a small proportion of receptors need to be activated to 
elicit a full calcium response16. Interestingly, the DL-compounds tested in both assays behave as full agonists 
in the Fluo-4 Ca2+-assay but as partial agonists in the IP-One assay. Moreover, racemic 7c and L-Trp behave 
as super-agonists compared to compound 1a (Table 6). The IP-One assay is thus superior in differentiating the 
efficacy of the compounds.
Collective SAR – A common motif of two terminal phenyl rings, R1 and R2, separated by a 
6-atom linker. The lowest energy conformations of the three most potent published reference agonists 1a, 7c 
and 39 demonstrated a near perfect overlay of their terminal phenyl rings, herein designated R1 and R2 (Tables 1, 
2 and 3), and a six atom linker with multiple polar groups (Supplementary Fig. 3). Below we present the first col-
lective SAR analysis of the three series, and our new analogues, which are summarized in the form of a common 
pharmacophore model (Fig. 4b) that refines our original model used for the virtual screening by incorporating 
the three latter (new) series.
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Figure 1. Chemical structure of the two endogenous amino acids L-Trp and L-Phe, and the most potent 
surrogate agonists 1a and 7c, and 39 from three series published by H. Lundbeck A/S11, Janssen R&D13,14, 
and Takeda15 respectively.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:36681 | DOI: 10.1038/srep36681
Linker length. The linker in 1a has a central nitrogen flanked by two amide groups (Table 1). 7c and 39 differ 
by having a carbon in the third position, in effect making the central portion of the linker a glycine moiety, and 
by having a methylated aliphatic carbon in the 6th position (Tables 2 and 3) instead of an aromatic carbon in 1a. 
Our new agonists (Table 4) display variations of either carbon or nitrogen atoms in the positions 3, 5 and 6, spe-
cifically: CNC (DL130–132), NCC (DL146), NCN (DL22 and DL144), and NNC (DL148).
Removal of the 5-nitrogen (DL96) in 1a resulted in loss of activity (Fig. 5), indicating that a reduction of the 
linker length cannot be tolerated. This is consistent with the presence of a shortened linker in many of the inactive 
analogues, such as DL3, DL5–8, DL15, DL47–48, DL51, DL55, DL59, DL61, DL95, and DL153 (Supplementary 
Chart 1). However, DL24, in which the 5-position and R2 are fused with a cyclohexyl, makes up an exception 
maintaining activity (EC50 = 431 nM) despite a shorter linker. Interestingly, DL24 matched the pharmacophore 
elements well by adopting an atypical out-of-plane conformation between the acceptor (A4) and the aromatic 
(R1) pharmacophore elements (Supplementary Fig. 4 and Supplementary Chart 1). This may suggest that the 
cyclization rescues activity by locking the orientation of the R2 phenyl, which is free to rotate in the closest inac-
tive analogues, DL6–8. We also found that generally compounds with linkers longer than 6-atoms, has decreased 
Cmpd R1 R2
Linker
EC50 (nM) Emax (%)
Pharmacophore 
Element/Commentpos-3 pos-5
1a 3,5-diMeO H N N 39 100 A2
1b H H N N 2,400 85 —
1c 2-MeO H N N 620 79 Exclusion volume at R1 2-pos
1d 2-EtO H N N ND* 53 Exclusion volumes around R1 2-pos.
1e 3,5-diEt H N N ND 6 Exclusion volume at R1 3- & 5-pos.
1f 3-MeO H N N 1000 100 A2
1g 4-F H N N 440 96 R1 & R2
1h 3,4,5-triMeO H N N 63 76 R1 & R2
1i 4-PhO H N N 2,100 61 No exclusion volume at R1 4-pos.
1j 3,5-diMeO 4-Br N N ND 73 Exclusion volumes at R2 4-pos.
1k 3,5-diMeO 4-CN N N ND 20 Exclusion volumes around R2 4-pos.
1l 3,5-diMeO 2-Me N N 86 86 Exclusion volumes at R2 2-pos.
1m 3,5-diMeO 4-Cl N N ND 64 Exclusion volumes at R2 4-pos.
1n 3,5-diMeO 5-Br N N ND 54 Exclusion volumes at R2 5-pos.
1o 3,5-diMeO 7-MeO N N ND 50 Exclusion volumes at R2 7-pos.
1p 3,5-diMeO H
N N
> 10000 ND A3
Linker pos-1: removal of = O
1q 3,5-diMeO H
N N
3300 100 D5Linker pos-2: N to C 
substitution
1r 3,5-diMeO H C N 180 98 —
1s 3,5-diMeO H N C 88 95 —
1t 3,5-diMeO H
N C
2500 74 D5
Linker pos-2 N-methylation
1u 3,5-diMeO H N-Methylated C 5100 84 —
Table 1.  Chemical structures and potencies of compounds 1a-u. Data from Shi et al.11. ND: not determined.
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activity such as compounds 73, 79 and 80 from Hitchcock et al.15 and our inactive ligands DL50, DL78, DL84, 
DL86, DL98, DL104, DL105, DL113, and DL155 (Supplementary Chart 1).
Linker hydrogen bond features. Removal of the 1-carbonyl oxygen atom (1p and 9 Dvorak et al.) 
results in loss of activity suggesting that it represents a critical hydrogen bond acceptor (feature A3 in Fig. 4b). 
Methylation (1t) or carbon substitution (1q) of the 2-nitrogen reduces the potency to the micromolar range 
suggesting that a hydrogen bond donor in this position is important (feature D5). The 2-nitrogen in 39 lacks 
a hydrogen bond donor feature, however, 39 and the rest of the Hitchcock et al. set can perfectly fit the sug-
gested pharmacophore model in a horizontally flipped manner (Supplementary Fig. 5) suggesting D5 is still a 
fair-to-assume pharmacophore feature based on all other ligand sets. In contrast, replacement of the 3-nitrogen 
with carbon (1r, and all 7a–q) has little effect on potency. Removal of the 4-carbonyl oxygen atom (8 – Dvorak 
et al.) results in loss of activity suggesting that it represents a critical hydrogen bond acceptor (feature A4). At the 
5-position, nitrogen to carbon substitution (1a to 1s) has a marginal (2-fold) effect. The new agonists DL131 and 
DL132 corroborate this as they maintain the same three moieties in positions 1, 2 and 4, while those in positions 
3 and 5 are both absent.
Linker conformational restraints. The series by Hitchcock et al.15 has a constrained linker at the 
2-position via a 4-oxo-3,4dihydrobenztriazene ring. This might be a beneficial strategy to lock the aromatic ring 
Cmpd R1 Linker EC50 (nM) Emax (%)
Pharmacophore 
Element/Comment
7a H Gly 162 ± 30 130 —
7b 2-Cl Gly 150 ± 23 120 —
7c 3-Cl Gly 16 ± 2 138 H6
7c (R) 3-Cl Gly 2,100 ND —
7d 4-Cl Gly 118 ± 49 117 —
7e 3-Me Gly 24 ± 5 137 H6
7f 3-CN Gly 59 ± 13 129 H6
7g 3-F Gly 54 ± 11 118 H6
7h 3-MeO Gly 33 ± 7 146 A2
7i 3-CF3 Gly 52 ± 17 134 H6
7j 3-OCF3 Gly 46 ± 22 129 A2
7k 2,3-diCl Gly 52 ± 21 113 —
7l 3,4-diCl Gly 193 ± 76 106 —
7m 2,5-diCl Gly 40 ± 14 139 —
7n 3,5-diCl Gly 46 ± 4 119 —
7o 3-Cl, 5-F Gly 24 ± 22 124 —
7p 3-Br, 5-Cl Gly 78 ± 8 113 —
7q 3,5-diMeO Gly 32 ± 7 149 A2
8 3-Cl Gly Linker pos-1: removal of = O > 10,000 ND A4
9 3-Cl Gly Linker pos-4: removal of = O > 10,000 ND A3
10 3-MeO L-Ala 66 ± 17 143
Exclusion volumes at 
linker 3-pos.
11 3-MeO D-Ala 440 ± 34 88
Exclusion volumes at 
linker 3-pos.
12 3-MeO L-Ser 283 ± 46 107
Exclusion volumes at 
linker 3-pos.
13 3-MeO L-Phe 10,000 ND
Exclusion volumes at 
linker 3-pos.
Table 2.  Chemical structures and potencies of compounds 7a–q. Data from Dvorak et al.13,14. The maximum 
efficacy (Emax) is relative to L-Trp. All data represent the mean of at least three different experiments. ND: not 
determined.
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and/or the linker 1–2 atoms in a favourable conformation. This is proved by the generally improved potencies in 
the Hitchcock analogues (e.g. 39 vs. 1a and 7c). In the series by Dvorak et al.13,14, the 3-carbon has been substi-
tuted to change the central Gly residue into Ala, Ser, and Phe (10–13). The S-(11), but not R-methylation (10), 
strongly reduced the potency (compared to 7h). In the Hitchcock et al.15 set, the same effect is seen in compounds 
50 and 51 (compared to 46). Furthermore, even with the favourable enantiomer, hydroxymethyl substitution (12) 
also leads to a significantly reduced potency. Thus, although part of the effect could be mediated by the action of 
the two flanking sides of the ligands, there is no room for bulk around the 3-position and exclusion volumes were 
placed accordingly (Fig. 4b). Moreover, the 1- (1p and 8) and 4-carbonyl (9) oxygen atom removal that abrogated 
Cmpd R1 R2 EC50 (nM)
Pharmacophore Element/
Comment
1 H H 54 R1 & R2 inclusion
3 2-MeO 4-Me 24 —
5 H 4-Me 9 Linker 6-Me can be S or R
6 H 4-Me 7 Linker 6-Me can be S or R
14 3-F 4-Me 11 H6 inclusion
18 3-MeO 4-Me 10 A2 inclusion
19 3-Cl 4-Me 13 H6 inclusion
28 3-Me 4-Me 10 H6 inclusion
35 4-Me 4-MeO 42 —
36 4-MeO 4-Me 19 —
37 4-MeO 4-MeO 37 —
39 2-Me 4-Me 6 —
43 3-MeF3 4-Me 45 —
50 H 4-Me & 2-MeO 52 Linker substitution conformation
51 H 4-Me & 2-MeO 16 Linker substitution conformation
60 3-MeO 4-MeF3 18 —
73 H H 1303 Longer linker length
79 H H ND Longer linker length
80 H H 288 Longer linker length
Table 3.  Chemical structures and potencies of selected compounds from Hitchcock et al.15 confirming the 
SAR analysis for GPR139 analogues.
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Figure 2. Concentration-response curves of the new GPR139 agonists measured on the NOVO-star using 
the Fluo-4 Ca2+-assay. The responses are normalized to EC100 of 1a (8 μ M) and are ordered by their potency 
(colour-scale: dark-blue > green > yellow). The graphs are one representative concentration-response curves out 
of at least three independent experiments performed in triplicates. Data points are means ± SD.
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activity may have done so partly because of the loss of the sp2 atom configuration, in addition to the loss of the 
hydrogen bond acceptor character.
DL132 (EC50 = 505 nM) and DL83 (EC50 > 10 μ M – very weak agonist) are cyclized between the 5- and 
6-positions. This has not been tested before, and it would be intriguing to investigate this cyclization on the two 
published series. As shown below, the 6-position is often fused with the R2 phenyl, but can also be aliphatic and 
methylated (7–13). Of note, both the 6-position (S) and (R) enantiomers of 7c13,14 as well as compounds 5 and 6 in 
the Hitchcock et al. set15 are potent, suggesting no preferred geometry in the binding pocket around this position.
Cmpd Structure EC50 (nM) Emax (%) 
DL43 364 97
DL126 411 91
DL24 431 109
DL22 442 105
DL132 505 94
DL130 888 89
DL85 1,021 95
DL131 1,088 101
DL144 1,155 96
DL148 1,216 100
DL154 1,500 91
DL146 4,715 85
Table 4.  Structures, potencies, and efficacies of the 12 new agonists as recorded in the Fluo-4 Ca2+-assay. 
Data represent the mean of at least three different experiments. Efficacies (Emax) are relative to 1a.
www.nature.com/scientificreports/
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Structures QPlogS (mol dm–3) QPlogPo/w PSA (Å2)
Hitchcock criteria 
match (Y/N)
#1 #2 #3 #4
R1
References − 1.70 1.95 16.40 Y N Y Y
− 2.40 2.90 0.00 Y Y Y Y
− 2.22 2.73 0.00 Y Y Y Y
Bioisosteres − 2.54 3.00 15.80 Y Y Y Y
− 1.23 1.50 18.70 Y N Y Y
− 1.77 1.32 28.24 Y N Y Y
R2
References − 3.60 3.35 0.00 Y Y Y Y
− 1.64 2.13 0.00 Y Y Y Y
Bioisosteres − 3.61 3.50 0.00 Y Y Y Y
− 2.05 2.20 13.90 Y Y Y Y
− 2.94 3.00 0.00 Y Y Y Y
− 4.60 4.00 9.00 Y Y Y Y
− 3.08 3.15 0.00 Y Y Y Y
Table 5. GPR139 bioisosteres with calculated solubility measures of QPlogS and QPlogPo/w. Blood-brain 
barrier penetration has been estimated by calculating the polar surface area (PSA) and matching (Yes/No) of the 
Hitchcock criteria18:#1 Sum of nitrogen and oxygen atoms (N + O) < 5, #2 QPlogP – (N + O) > 0, #3 PSA  
< 90 Å2, #4 MW < 450.
www.nature.com/scientificreports/
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R1 substitution and bioisosteres. Removal of one of the 3,5-diMeO groups reduces potency by ~26-fold 
in the Shi et al. series (1f vs. 1a), but has no effect in the series by Dvorak et al. (7h vs. 7q), which contains several 
additional equipotent single or double substituted analogues: methyl (7e), trifluoromethyl (7i), methoxy (7h, 7q) 
trifluoromethoxy (7j), cyanonitrile (7f), and several halogens (F: 7g; Cl/F: 7o, Br/Cl: 7p). This is also seen in the 
Hitchcock et al.15 series where R1 has a 3-methoxy (e.g. 18 and 60), methyl (e.g. 28), triflouromethyl (e.g. 43), or 
several halogens (e.g. F: 14; Cl: 19). Together, this suggests the combined 3,5-substitution is not needed to main-
tain potency. Interestingly, the alternative pattern of 2,3- (7k) and 2,5-dichloro- substitution (7m) is equipotent 
to the 3,5-pattern (7n), but unlike the single 3-chloro (7c), the 2-chlorosubstituent (7b) alone displays a slightly 
reduced potency (~3-fold). This is in line with the series by Shi et al.11 and Hitchcock et al.15 in which a single 
methoxy in the 2-position (1c, and 3, respectively) is (~16- and 5-fold) less potent than the 3,5-diMeO reference 
(1a, and 39). This SAR at the 2-position is shared by the 4-position (35, 37 and 1j–m): A third methoxy group into 
the 4-position (1h) of 1a shows that the substituent can be accommodated, however the single substituent alone 
(methyl: 35, methoxy: 37, fluoro: 1g, chloro: 7d, and phenoxy: 1i) is not enough to maintain very high activity. 
Collectively, this shows that the 3-position is essential and can hold either a hydrophobic/halogen or acceptor 
element (H6/A2), whereas the 2,4, and 5-substitutions are optional (1f, and 36 being exceptions).
With regard to the size of R1 substituents, ethyloxy-substitution in the 2- (1d), and di-ethyl in the 3 and 
5-positions (1e) abrogates and significantly reduces activity, respectively (represented as exclusion volumes 
placed on the third atoms in all of the positions 2,3, and 5). However, smaller substituents on the 2-position 
(39) can be accommodated in the Takeda set and none of the added exclusion volumes are in contradiction 
with any of those substituents (Supplementary Fig. 4). In contrast, the 4-position can accommodate the large 
1-ethyl-2-methyl-benzoimidazole bioisostere found in multiple active compounds (DL43, DL85, DL164 and 
DL148). Finally, all active surrogate agonists present an R1 terminal aromatic ring in our series, Shi et al.11, 
Dvorak et al.13,14, and Hitchcock et al.15, which likely contributes to the potency (feature R1 in Fig. 4b).
The new agonists span three 3,5-diMeO/3-Cl/ 2-Me-phenyl bioisosteres: 1-ethyl-2-methyl-benzoimidazole, 
benzo[d][1,3]dioxole, and 1H-benzo[d]imidazole (Table 5). The two most potent new agonists share the distal 
naphthyl (R2) moiety of 1a, while the 3,5-diMeO phenyl (R1) is replaced with 1-ethyl-2-methyl-benzoimidazole 
(DL43) or benzo[d][1,3]dioxole (DL126). Their potencies are ~10-fold lower than that of 1a (in the Fluo-4 
Figure 3. IP-One HTRF® assay measuring Gq activation. Concentration-response curves of 1a, 7c (racemic), 
L-Trp, L-Phe, DL43, DL126, DL24, DL22, DL132 and DL130 on (A) CHO-139 and (B) CHO-M1 in the IP-One 
assay (final conc of LiCl = 20 mM). The dotted line represent the [IP1] response from (A) 10 μ M 1a and  
(B) 1 μ M carbachol, which is an agonist for the muscarinic acethylcholine receptor M1 that activates the Gq 
coupled pathway. The graphs are means ± SEM based on three independent experiments performed in triplicates.
Cmpd EC50 (μM) Emax (%)
7c (racemic) 0.49 120(*)
DL24 0.75 40
1a 1.05 100
DL132 4.16 77
DL22 4.18 69
DL130 4.98 19
DL126 5.62 38
DL43 9.57 65
L-Phe 4,454 95
L-Trp ~8,500 106(**)
Table 6.  Potencies and efficacies of 7c, 1a, L-Trp, L-Phe, DL43, DL126, DL24, DL22, DL132 and DL130 
as recorded in the IP-One HTRF® assay. Data represent the mean of at least three independent experiments 
performed in triplicates. Efficacies (Emax) are relative to compound 1a. (*)= The Emax for 7c is based on the highest 
concentration tested (10 μ M). (**)= The Emax for L-Trp is based on the highest concentration tested.(20 mM).
www.nature.com/scientificreports/
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Ca2+-assay) but part of this could be attributed to a nitrogen-to-carbon substitution at linker position 5 (led to 
~2.4-fold reduction in 1s vs. 1a). Thus, these two bioisosteres are likely to be nearly equipotent to the reference 
3,5-diMeO- and 3-Cl-phenyl moieties. Moreover, our R1 bioisosteres have polar surface area (PSA) and solubility 
(QPlogS, QPlogPo/w) values comparable to the parent moieties in 1a, 7c, and 39 (Table 5).
R2 substitution and bioisosteres. The series by Dvorak et al.13,14 and Hitchcock et al.15 showed that the 
1a naphthyl can be replaced by a benzyl-ethyl, i.e. the distal of the two fused aromatic rings is sufficient to main-
tain the high potency (feature R2 in Fig. 4 was moved accordingly). Our data showed that replacing the terminal 
phenyl ring R2 with a hetero-aromatic ring system, e.g. DL8, DL20 and DL40 (Supplementary Chart 1), led to a 
complete loss of activity. In the Shi et al. series, substitutions in the aromatic ring closest to the linker, could be tol-
erated in the 2-position (methyl: 1l), but not any of the 4-(bromo: 1j, cyanonitrile: 1k, chloro: 1m), 5-(bromo: 1n), 
or 7-positions (methoxy: 1o). Furthermore, inactivity was also observed for several compounds with bulky sub-
stituents: di-phenylmethyl (DL94, DL80), cyclopentyloxyphenyl (DL134), and pyridinylmethylmorpholine 
(DL135). However, the large DL85 and DL148 make up exceptions able to exhibit activity (EC50 = 1.02 μM and 
4.7 μ M, respectively). In the series by Hitchcock et al. small substitutions on R2 seems tolerable and sometimes 
even favourable (1 vs. 5). Taken together, this suggests a tight fit to the receptor-binding cavity in some positions 
around R2 (exclusion volumes are added at positions 4, 5 and 7 accordingly).
Figure 4. Comparison of the original and new pharmacophore models. (a) The original pharmacophore 
model used to identify the new agonists, and (b) the refined pharmacophore model based on the currently 
presented SAR analysis. Compound 1a is shown with green carbons. Pharmacophore features are: Red: 
hydrogen bond acceptor, Blue: hydrogen bond donor, Green: hydrophobic element, Orange: aromatic system, 
and Yellow: exclusion volume (eliminates matching of substituents resulting in activity loss).
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The new agonists span five 1a naphthyl/7c, 39 benzyl bioisosteres: 5,6,7,8-tetrahydronaphthyl, 
1,2,3,4-tetrahydroquinoline, thiochromane, naphtha[2,1-b]furan, and 2,3-dihydro-1H-indene (Table 5). All bio-
isosteres are fused ring systems with a non-aromatic first ring, except the naphtha[2,1-b]furan, which notably 
has three fused aromatic rings. Similar to R1, our R2 bioisosteres have polar surface area and solubility values 
comparable to the parent moieties in 1a, 7c, and 39 (Table 5).
Common pharmacophore model. Pharmacophore composition. The above collective SAR was used to 
construct the updated pharmacophore model in Fig. 4B, and the detailed mapping of analogues into features is 
listed in the last columns of Tables 1–3. The pharmacophore contains two terminal aromatic features (R1 and R2) 
separated by a linker containing two hydrogen bond acceptors (A3 and A4), and one hydrogen bond donor 
(D5). An additional dual hydrophobic/halogen or acceptor element, H6/A2, is placed at position 3 of R1. Finally, 
exclusion volumes (yellow) have been incorporated to block substituents rendering a reduction or loss of activity.
Pharmacophore Validation. The updated pharmacophore model was matched against all 126 agonists described 
herein, and 6300 property-matched decoys generated by DUD-E17 (50 decoys/ligand). The pharmacophore 
matched all known agonists, including the new analogues described herein. A receiver-operating characteristic 
(ROC) analysis displayed an area under the curve of 0.87 (Fig. 6). The early enrichment (top 1% of matches) 
was 72% actives, and strikingly 80% of all actives were retrieved already in the first 22% of the entire set, dis-
playing both a good selectivity and sensitivity of the pharmacophore model. Matching of the same set of com-
pounds against our original pharmacophore model (only based on the set by Shi et al.11) displayed a significant 
improvement (Supplementary Fig. 7). Our refined pharmacophore model successfully filtered out inactive ana-
logues due to the added exclusion volumes, which did not hinder matching of the new series by Hitchcock et al.15  
(Supplementary Fig. 6). Collectively, this suggests that the new pharmacophore model can be used to find poten-
tially active analogues in future prospective screenings.
Discussion
The new bioisosteres and the common SAR analysis present features that could be useful in future medicinal 
chemistry and optimisation studies. For example, a 7c naphthyl to benzyl substitution would be an interest-
ing combination of two of the three published series. From the new linker variants, cyclization of the linker 5- 
and 6-positions, as in DL132, on the three published series could explore the conformational restraining of the 
R2-naphthyl and benzyl systems. Additionally, the necessity of the linker 1-position carbonyl oxygen’s lone pair 
as a hydrogen bond acceptor is clear, but a carbonyl bioisostere, such as a spiro-oxetane, should provide the same 
electronic function while also testing a slight increase in steric bulk in a region devoid of exclusion volumes. On 
the other hand, constraining the linker 2-position via cyclization with a 4-oxo-3,4-dihydro-benzotriazene ring as 
in 39 and the rest of the Hitchcock series, showed a potential beneficial effect for the activity. Furthermore, some 
of the new bioisosteres might be able to give equivalent or close potencies if introduced to otherwise identical 
analogues of the reference ligands, while offering slightly modified solubility and polar surface areas (PSA) as 
described below.
As mentioned by Shi et al. it would be beneficial for brain penetration to reduce the polar surface area of 
GPR139 agonists11. Blood-brain barrier penetration is achieved when PSA is lower than 90 Å2 18, and the PSA 
of 1a is just short of this, 88.70 Å2. 1s displays an improved PSA of 76.7 Å2, but failed to increase brain expo-
sure due to low plasma levels11. In contrast, 7c displays good cellular permeability (and no efflux potential), 
and a brain to plasma ration of 1.214. Some of our bioisosteres could offer slightly more beneficial PSA values 
(Table 5). For R1, the PSA of 1-ethyl-2-methyl-benzoimidazole is slightly less than that of 3,5-diMeO-phenyl in 
Figure 6. ROC – Plot of the pharmacophore matching of all published, new compounds, and set of DUD-E 
generated decoys17. The area under the curve is 0.87, and the top 1% includes 72% actives, and 80% of the 
actives are matched in the first 22% of the screening set, demonstrating a very high discrimination of the active 
from inactive compounds.
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1a, and the benzo[d][1,3]dioxole has a comparable value. For R2, 5,6,7,8-tetrahydronaphthyl, thiochromane, and 
2,3-dihydro-1 H-inden have equivalent PSA values to the two reference systems.
The PSA must be balanced with the solubility estimated with recommended QPlogS19 values between − 1 
and − 6 mol/dm–3; to achieve CNS penetration typically a QPlogPo/w value below 3.5 is desired. The most soluble 
R1 bioisosteres are: benzo[d][1,3]dioxole > 1H-benzo[d]imidazole = 3,5-diMeO-phenyl (1a) > 7c 3-Cl-Phenyl, 
while 1-ethyl-2-methyl-benzoimidazole is comparable to 7c 3-Cl-Phenyl. For R2, 1,2,3,4,tetrahydroquinoline, 
thiochromane, and 2,3-dihydro-1 H-inden have equivalent or better solubility than 1a. However, the benzyl in 7c 
remains the option with the lowest values.
Conclusions
In the present study we identified 12 GPR139 agonists (EC50 = 364 nM to 4.7 μ M) containing previously untested 
aromatic bioisosteres, as well as novel linker variants. Our compounds were incorporated in the first combined 
SAR study of the three most potent series published by Lundbeck A/S, Janssen R&D and Takeda Ltd. This SAR 
was used to suggest a refined common pharmacophore model, which was able to discriminate between active and 
inactive compounds. The two proposed endogenous agonists L-Trp and L-Phe overlay with R1 and R2, respec-
tively as well as additional linker functionalities (Supplementary Fig. 8) showing that they too are likely to be 
accommodated by the common pharmacophore and the same binding site. This study could serve to guide the 
future ligand identification and optimization efforts. Studies to characterize the pharmacology and function of 
GPR139, as well as to identify antagonist tool compounds, are ongoing.
Methods
Ligand preparation and conformational search. LigPrep20 was used for ligand preparation. Default 
QikProp21 settings were used to calculate PSA, QPlogS, and QPlogPo/w values. Macromodel22 was employed to do 
the conformational analysis on the three potent ligands 1a, 7c, and 39 using default settings. This includes using 
the OPLS_3 force filed23, and the Monte Carlo approach for sampling the different conformations. The global 
energy non-collapsed conformation of the ligands was picked for further analysis and superposition. Hitchcock 
criteria18: Sum of nitrogen and oxygen atoms (N + O) < 5, ClogP – (N + O) > 0, PSA < 90 Å2, and MW < 450 
were also employed to assess the bioisosteres.
Pharmacophore screening. The screening database, eMolecules plus24 (~6 million drug-like compounds), 
was prepared with LigPrep25 to desalt, add hydrogen atoms and generate tautomers, stereoisomers (max 32) and 
3D conformations (max 10 ring conformations). Epik and the OPLS 2005 force field26 were applied to generate 
charge states at pH: 7.0 ± 1.022. LigFilter was used to remove structures with reactive functional groups. The Phase 
database was prepared with 100 maximum conformers, up to 10 conformations per rotatable bond, thorough 
conformational sampling, conformational variation of amide bonds and a maximum relative energy difference 
of 6.0 kcal/mol.
Hit and analog purchases. A minimum of four matching pharmacophore10 elements was required and a 
preference was set for partial matches involving more sites. Hits were sorted by fitness score and clustered with 
Canvas27 to select diverse representative structures. After the first assaying round small structure-activity rela-
tionship analyses were conducted and the compounds sorted into lead ligand series. The selections of analogs 
were based on substructures drawn in MarvinSketch and queried in the eMolecules database loaded into Instant 
JChem (Marvin 5.12.3, 2014 and Instant JChem 6.2.0, 2014, ChemAxon, www.chemaxon.com). Compounds 
were purchased from Enamine (Kiev, Ukraine).
Compounds and buffers. Compound 1a11 was kindly provided by H. Lundbeck A/S, Denmark. Compound 
7c (Enamine no: Z31449867) was tested as a racemate, as the (S)-form described by Janssen et al. was not com-
mercially available. All compounds were dissolved to 20 mM in DMSO (Sigma, D2650) and subsequently diluted 
in a HEPES buffer (HBSS (Invitrogen, 14025) supplemented with 20 mM HEPES + 1 mM MgCl2 + 1 mM CaCl2, 
pH = 7.4) to a final concentration 0.5% DMSO in the assay. The DMSO level was kept constant for all con-
centrations of all compounds. DMSO was confirmed not to have any activity by itself at this concentration10. 
L-Tryptophan (T0254) and L-Phenylalanine (P2126) were obtained from Sigma-Aldrich and dissolved directly 
in buffer.
Cell lines. All compounds were tested on a CHO-k1 cell line stably expressing GPR139 (CHO-GPR139) 
kindly provided by H. Lundbeck A/S, Denmark, and also on a CHO-k1 cell line stably expressing the M1 
receptor (CHO-M1) (The Missouri S&T cDNA Resource Center, #CEM100TN00) to check for specificity. The 
CHO-GPR139 was grown in Dulbecco’s modified eagle medium (DMEM) F12-Kaighn’s (Gibco, 21127) sup-
plemented with 10% dialysed fetal bovine serum (Gibco, 26400, United States origin), 1% GlutaMAXTM-I 
(100X) (Gibco, 35050), and 100 units/mL penicillin and 100 μ g/mL streptomycin (Gibco, 15140) and 1.0 mg/
mL geneticin (Invitrogen, 1181103). CHO-M1 was grown in Ham’s F12 (Gibco, 21765) supplemented with 10% 
fetal bovine serum (Gibco, 10270, South America origin) + 100 units/mL penicillin and 100 μ g/mL streptomycin 
(Invitrogen, 15140–122) and 0,25 mg/mL geneticin (Life Technologies, 11811–031). Compound 1a and carba-
moylcholine chloride (Sigma-Aldrich, C4382) were used as positive controls in the two cell lines, respectively.
Ca2+-Fluo-4 assay. 30.000 cells/well were plated in black 96-well plates with flat clear bottoms (Corning, 
Falcon, 353219) and incubated overnight. The Fluo-4 dye loading solution (Invitrogen, F36206) was prepared 
according to the manufacturer’s instructions by dissolving it in HEPES buffer supplemented with 2.5 mM 
probenecid. 50 μ L dye loading solution was added to each well. Cells were incubated with the Fluo-4 dye for 
60 min at 37 °C, then washed with 100 μ L HEPES buffer. 100 μ L HEPES buffer supplemented with 2.5 mM 
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probenecid was then added to each well and incubated in 10 minutes at 37 °C before measurement. 33 μ L of the 
test compounds (4x concentrated) were added automatically after baseline measurements. Intracellular calcium 
change was recorded on a NOVOstar instrument (BMG Labtech) at 37 °C with an excitation filter of 485 nm and 
an emission filters 520 nm. Data originate from three independent experiments in triplicates.
IP-One assay. The IP-One assay was performed as described in the work by Thomsen et al.28, with few modi-
fications. Breifly, CHO-139 and CHO-M1 were detached and re-suspended to a concentration of 10 million cells/
mL. 5 μ L 2x concentrated compound (+ 40 mM LiCl) and 5 μ L cell suspension (50,000 cells/well) was mixed. The 
plate was sealed and incubated at 37 °C for 1 hour. Next, 10 μ L detection reagents (lysis buffer containing 2.5% 
Eu3+-anti-IP1 antibody and 2.5% IP1-d2) was added and the plate was incubated for 1 hour at room temperature. 
The plate was read on an Envision (PerkinElmer, Waltham, MA, USA). The time resolved-fluorescence resonance 
energy transfer (TR-FRET) 665 nm/615 nm ratio, which is inversely proportional to the inositol monophosphate 
(IP1) accumulation, was used to determine the concentration of the IP1 response.
cAMP assay. The cAMP assay was performed as described in the work by Thomsen et al.28 with few modi-
fications. Breifly, CHO-139 and CHO-M1 was detached and resuspended to a concentration of 1 million cells/
mL. 5 μ L 2x concentrated compound (for Gs: + 100 μ M IBMX and for Gi: + 100 μ M IBMX + 10 μ M forskolin 
(Fsk)) and 5 μ L cell suspension (5,000 cells/well) was mixed. The plate was sealed and incubated at room tem-
perature for 30 min. Next, 10 μ L detection reagents (lysis buffer containing 2.5% Eu3+-anti-cAMP antibody and 
2.5% cAMP-d2) was added and the plate was incubated for 1 hour at room temperature. The plate was read on 
an Envision (PerkinElmer, Waltham, MA, USA). The TR-FRET 665 nm/615 nm ratio, which is inversely propor-
tional with the cAMP production, was used to determination the concentration of the cAMP response.
Generation of a common pharmacophore model. Phase version 4.529 was used to build the new phar-
macophore model based on compounds from all GPR139 agonist series (Tables 1–4). Ligand conformations were 
generated with the thorough sampling option and hypotheses matching the variant AAADHRR (A hydrogen 
bond acceptor, D hydrogen bond donor, H hydrophobic group, and R aromatic ring) were taken into consid-
eration. The EC50 cut-off was set to 1 μ M and the hypothesis matching the defined elements was selected after 
scoring active and inactive compounds. Exclusion volumes were added to exclude inactive ligands volume sizes 
were defined based on the size of disfavoured substituents. 2D structures were drawn in MarvinSketch30 and 3D 
structures were visualized in PyMOL31.
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